Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q31153083
Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fractureQuality of life issues in men undergoing androgen deprivation therapy: a reviewMolecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP.Coexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer.Diethylstilboestrol for the treatment of prostate cancer: past, present and future.ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-AnalysisHsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer.Estrogens and prostate cancer: etiology, mediators, prevention, and management.Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal OestradiolSystemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice.Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.Comment on 'Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'.Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
P2860

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q31153083
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Early hormonal data from a mul ...... or metastatic prostate cancer.
@ast
Early hormonal data from a mul ...... or metastatic prostate cancer.
@en
type
label
Early hormonal data from a mul ...... or metastatic prostate cancer.
@ast
Early hormonal data from a mul ...... or metastatic prostate cancer.
@en
prefLabel
Early hormonal data from a mul ...... or metastatic prostate cancer.
@ast
Early hormonal data from a mul ...... or metastatic prostate cancer.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Early hormonal data from a mul ...... or metastatic prostate cancer
@en
P2093
P2860
P304
P31
P356
10.1111/J.1464-410X.2008.07583.X
P433
P478
P50
P577
P5875
P698
P921
P932